SCHEMBL5136567

SCHEMBL5136567

CCCCC(c1cnc(-c2ccccc2)n1CCCC)N(CCCC)Cc1ccc(OC(F)(F)F)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 5/20 0.38
PPARA Q07869 2/20 0.38
KCNH2 Q12809 1/20 0.38
TSHR P16473 1/20 0.36
ALOX5 P09917 1/20 0.36
PPARG P37231 1/20 0.36
CNR2 P34972 1/20 0.35
TRPM8 Q7Z2W7 5/20 0.33
CETP P11597 1/20 0.33
SERPINE1 P05121 1/20 0.33
ATP1A1 P05023 1/20 0.33
ATP1B1 P05026 1/20 0.33
ATP1A3 P13637 1/20 0.33
ATP1B2 P14415 1/20 0.33
ATP1A2 P50993 1/20 0.33
ATP1B3 P54709 1/20 0.33
FXYD2 P54710 1/20 0.33
ATP1A4 Q13733 1/20 0.33
BCHE P06276 1/20 0.33
GCGR P47871 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5071417 0.89 TSHR (0.39) PPARDTSHRBCHE
SCHEMBL5136624 0.85 TSHR (0.40) TSHRBCHE
SCHEMBL5136261 0.85 TSHR (0.35) PPARDPPARATSHRPPARG
SCHEMBL5136829 0.84 TSHR (0.39) TSHRCNR2
SCHEMBL650145 0.83 LPAR1 (0.40) TSHR
SCHEMBL5134552 0.83 TSHR (0.40) PPARDTSHRBCHE
SCHEMBL5135939 0.81 HSP90AA1 (0.38) TSHRCNR2
SCHEMBL5135337 0.80 TSHR (0.37) PPARDPPARATSHRPPARGBCHE
SCHEMBL5134566 0.80 TSHR (0.41) TSHRBCHE
SCHEMBL5136148 0.79 OPRK1 (0.40) TSHRBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed